Products Affected - Description
Erythrocin powder for solution for injection, Hospira
500 mg, vial, 10 count (NDC 00409-6482-01)
500 mg, ADD-Vantage vial, 10 count (NDC 00409-6476-44)
Reason for the Shortage
Pfizer (Hospira) has Erythrocin on shortage due to manufacturing delays.
There is insufficient supply for usual ordering.
Estimated Resupply Dates
Pfizer (Hospira) has Erythrocin 500 mg vials on back order and the company estimates a release date of early-November 2016. The 500 mg ADD-Vantage vials are on intermittent back order with regular releases.
September 22, August 29, 10 and 5, July 11, 2016, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins